Close Menu

NEW YORK – Promega said on Tuesday that it has received CE marking for its OncoMate MSI Dx Analysis System, allowing it to make the test available as an in vitro diagnostic medical device in Europe.

OncoMate MSI is a PCR-based assay that measures microsatellite instability status in tissue samples from solid tumors. According to Promega, the kit offers high analytical sensitivity and specificity with a short turnaround time.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.